Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
Nature Medicine1995Vol. 1(8), pp. 792–797
Citations Over TimeTop 1% of 1995 papers
Nancy E. Kohl, Charles A. Omer, Michael W. Conner, Neville J. Anthony, Joseph P. Davide, S. J. DESOLMS, Elizabeth A. Giuliani, Robert Gomez, Samuel Graham, Kelly Hamilton, Laurence Handt, George D. Hartman, Kenneth S. Koblan, Astrid M. Kral, Patricia Miller, Scott D. Mosser, Timothy J. O’Neill, Elaine Rands, Michael D. Schaber, W. Wayt Gibbs, Allen Oliff
Related Papers
- → Protein Farnesyltransferase Catalyzes Unanticipated Farnesylation and Geranylgeranylation of Shortened Target Sequences(2020)29 cited
- → Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines(1997)239 cited
- → Identification of Novel Peptide Substrates for Protein Farnesyltransferase Reveals Two Substrate Classes with Distinct Sequence Selectivities(2009)71 cited
- → Farnesyltransferase Inhibitor as Anticancer Agent(2009)54 cited
- → Quantitative Determination of Cellular Farnesyltransferase Activity: Towards Defining the Minimum Substrate Reactivity for Biologically Relevant Protein Farnesylation(2014)7 cited